This article is mentioned in:

Mol Med Rep 11: [Related article:] 4047–4052, 2015; DOI: 10.3892/mmr.2015.3309

Following the publication of this article, an interested reader drew to our attention anomalies associated with the presentation of Figs. 1 and 4. The image selected for Fig. 1A, the data pertaining to '2 h', was inadvertently selected for Fig. 4A, the image labeled 'Sham'. Additionally, in Fig. 4, the same source image had inadvertently been used to provide the images for the 'Low dose group' and 'Model' panels (although the view presented differed in these panels). On re-examining our data, we realized that these errors had occurred during the compilation of Fig. 4, and that the images were correctly selected for Fig. 1. An amended version of Fig. 4 is presented below, featuring images which correctly show the data for the 'Low dose', 'Sham' and 'Model' groups. The immunohistochemical results suggested that, following treatment with 27 g/kg naotaifang extract, the expression of Fpn increased significantly compared with the other treatment doses (P<0.05), whereas significant changes were not observed among the other groups (P>0.05). The errors made in the selection of certain images for Fig. 4A did not affect the overall conclusions reported in the present study. We sincerely apologize for this mistake, and thank the reader of our article who drew this matter to our attention. Furthermore, we regret any inconvenience this mistake has caused.

Figure 4 Fpn expression in the hippocampal CA2 area at different doses detected by immunohistochemistry. (A) Immunohistochemistry results of the Sham surgery group, model group, low-dose group (3 g/kg NTE), medium-dose group (9 g/kg NTE) and high-dose group (27 g/kg NTE). (B) IOD of Fpn among all the groups. P<0.05 for comparisons between bars labelled with different letters. Fpn, ferroportin; IOD, integral optical density; NTE, naotaifang extract.